UC San Diego
UC San Diego Previously Published Works

Title
Nephrolithiasis and Polycystic Ovary Syndrome: A Case-Control Study Evaluating Testosterone and Urinary Stone Metabolic Panels.

Permalink
https://escholarship.org/uc/item/168866xrr

Authors
Fedrigon, Donald
Alazem, Kareem
Sivalingam, Sri
et al.

Publication Date
2019

DOI
10.1155/2019/3679493

Peer reviewed
Research Article

Nephrolithiasis and Polycystic Ovary Syndrome: A Case-Control Study Evaluating Testosterone and Urinary Stone Metabolic Panels

Donald Fedrigon III, Kareem Alazem, Sri Sivalingam, Manoj Monga, and Juan Calle

Cleveland Clinic, Glickman Urological & Kidney Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA

Correspondence should be addressed to Juan Calle; callej@ccf.org

Received 24 March 2019; Accepted 9 September 2019; Published 17 October 2019

Academic Editor: Kostis Gyftopoulos

Copyright © 2019 Donald Fedrigon III et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Both elevated testosterone and polycystic ovary syndrome (PCOS) have been speculated as possible risk factors for kidney stone formation; however, the details of this potential relationship with regards to 24-hour urine metabolic panels and stone composition have not previously been characterized. Methods. A total of 74 PCOS patients were retrospectively identified and matched with a cohort of female stone formers at a 3:1 ratio (by age and BMI). All patients had 24-hour urinary metabolic panels and stone compositions. These groups were compared using Pearson chi-square and Student t-tests. Additionally, the PCOS group was differentiated based on free testosterone using multivariate analysis. Results. The case-control cohort showed that PCOS patients had significantly lower sodium excretion \( (p = 0.015) \) and hypernatriuria rates \( (28.9\% \text{ vs } 50.9\%, \ p = 0.009) \). The PCOS-testosterone cohort demonstrated that high testosterone patients had significantly higher citrate values \( (p = 0.041) \) and significantly lower odds of hypocitraturia \( (36.7\% \text{ vs } 54.2\%, \ OR = 0.2, \ p = 0.042) \). The high testosterone group also had higher sodium excretion \( (p = 0.058) \) with significantly higher odds of having hypernatriuria \( (40.0\% \text{ vs } 13.6\%, \ OR = 13.3, \ p = 0.021) \). No significant patterns were revealed based on stone composition analysis. Conclusions. Compared to healthy stone formers, PCOS patients did not demonstrate significant differences in 24-hour urine and stone composition values. Elevated free testosterone in PCOS patients has a significant association with higher urinary citrate and sodium values: findings that in and of themselves do not confirm the hypothesized increased risk of stone formation. This patient cohort may provide deeper insight into the interplay between androgens and stone formation; however, further study is needed to fully characterize the possible relationship between PCOS and stone formation.

1. Introduction and Objective

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by oligomenorrhea and androgen excess, which affects 5–10% of women at reproductive-age and has been suggested to be a potential risk factor for stone formation [1, 2]. Elevated testosterone has been implicated as a causal factor in kidney stone formation based on a variety of inferential evidence: the incidence of urolithiasis is 2-3 times higher in men than in women, the risk of stone formation is reduced in castrated rats, as well as male stone formers having higher serum total testosterone levels than stone-free controls [3–8]. Our goal was to evaluate the relationship between PCOS, elevated testosterone, and stone formation from the perspective of stone composition and 24-hour urine metabolic stone panels.

2. Methods

2.1. Study Design. We retrospectively identified 74 patients from the Cleveland Clinic stone registry (ICD-9 592.xx and 594.xx) with diagnosis of PCOS (ICD-9 256.4) who had a recorded free testosterone level and 24-hour urinary collection. A matched cohort of female stone formers, matched by age and BMI on the date of 24-hour urine collection, was generated from our registry at a 3:1 ratio, for a total of 222
control patients. Patients were selected from our database in the timeframe from Oct. 2002 to Jul. 2014. If multiple testosterone values were available, the result closest in time to the date of the 24-urine collection was used. The PCOS patients were divided into normal and high (>6.4 pg/mL) testosterone groups based on previously published reference values [9].

2.2. Metabolic and Laboratory Evaluation. Stone composition was analyzed by Fourier transform infrared spectrometry and expressed as the amount of each component in the stone. Studied components were calcium oxalate monohydrate (CaOMH), calcium oxalate dihydrate (CaODH), calcium phosphate (CaPh), calcium hydrogen phosphate (CaHPh), magnesium ammonium phosphate (MAP), and uric acid (UA). A stone was considered pure if 70% or greater of the stone was composed of a single component. Patient urinary risk factors for stone disease were evaluated by 24-hour urine collection with the patient on an unrestricted diet. Urine samples were examined for calcium, sodium, oxalate, citrate, UA, volume, and creatinine. Urinary normal values were set using specific methodologies, including calcium less than 200 mg per day for women by the o-cresolphthalein complexon method, sodium less than 150 mmol per day by ion-selective electrode, oxalate less than 40 mg per day by enzyme immunoassay, citrate greater than 550 mg per day for women by enzyme immunoassay, UA less than 750 mg per day for women by the uricase method, and volume 2,000 ml or greater per day. Urinary creatinine was measured by the enzymatic method. Serum-free testosterone was evaluated by liquid chromatography tandem mass spectrometry (LC/MS/MS).

2.3. Study Endpoints. Primary endpoints for both sets of analysis were 24-hour urinary metabolic panels and stone composition. We compared baseline 24-hour urinary metabolic panels within both the case-control and PCOS-testosterone cohorts by absolute levels of all parameters and the proportion of patients with specific abnormalities. We compared stone composition by the relative amount of each component in the stone, mixed/pure status, and proportion of patients with each pure stone type. When multiple stones or stone fragments were passed or retrieved surgically for a single episode of nephrolithiasis, they were sent for analysis as a single sample.

2.4. Medications and Comorbidities. Registry patients were not included in either the PCOS or control group if their 24-hour urinary metabolic panel overlapped with medications such as thiazides, citrates, or allopurinol that could impact stone formation or urine metabolic panels. Medications commonly used in the treatment of PCOS (i.e., oral contraceptives, spironolactone, and metformin) and common comorbidities (i.e., diabetes mellitus and hypertension) were evaluated for potential confounding effects on free testosterone levels. Only metformin was found to have a potential confounding effect and was therefore included, along with age and BMI, as an adjusted variable in multivariable analysis.

2.5. Statistical Analysis. Statistical analysis was performed using R Statistical Software (R Foundation for Statistical Computing, Vienna, Austria). Case-control and PCOS testosterone group means were compared using Student t-tests and group percentages were compared using Pearson chi-square. Within the PCOS cohort, endpoints were also compared using multivariable linear and logistic regression, adjusted for age, BMI, and metformin status. For all tests, \( p < 0.05 \) was considered statistically significant.

3. Results

3.1. Urinary Stone Panel: Case-Control Cohort. We identified 88 PCOS patients in our stone registry, of which 14 were excluded based on medications that could impact 24-hour urine results. Demographic characteristics as well as the urinary calcium, citrate, creatinine, oxalate, uric acid, and volume were similar between the PCOS and control groups (Table 1). The 24-hour urine metabolic panels for the case-control cohort revealed that PCOS patients had both significantly lower urinary sodium excretion (\( p = 0.015 \)) and lower frequency of hypernatriuria (28.9% vs 50.9%, \( p = 0.009 \)). Urinary citrate was higher in the PCOS group (624.1 ± 361.9) than that in the control group (527.5 ± 317.8) but this did not reach statistical significance (\( p = 0.08 \)).

3.2. Urinary Stone Panel: PCOS Testosterone Cohort. Within the 74 eligible PCOS patients, 38 (51.3%) were classified as having high free testosterone (>6.4 pg/mL). Diabetes (\( n = 11 \)), hypertension (\( n = 25 \)), spironolactone (\( n = 8 \)), and oral contraceptive (\( n = 16 \)) status were all evaluated as potential confounding variables for both nominal and continuous testosterone values but not found to be statistically significant. High testosterone classification was significantly associated with younger age (\( p = 0.008 \)), higher BMI (\( p < 0.001 \)), and active metformin therapy (\( p = 0.05 \)). PCOS patients on metformin also had significantly higher free testosterone values (\( p = 0.026 \)). Therefore, BMI, age, and metformin status were included as confounding variables in the multivariate analysis. Table 2 shows the original data analysis and significance values for the PCOS testosterone cohort.

Multivariable analysis revealed that high testosterone patients had significantly higher urinary citrate values (\( p = 0.041 \), Table 3) with significantly lower odds of having hypocitraturia (36.7% vs 54.2%, OR = 0.2, \( p = 0.042 \)). High testosterone PCOS patients also had higher urinary sodium that approached statistical significance (\( p = 0.058 \)) with significantly higher odds of having hypernatriuria (40.0% vs 13.6%, OR = 13.3, \( p = 0.021 \)). Additionally, high testosterone PCOS patients had a higher average urinary volume output (\( p = 0.066 \)) and a decreased frequency of
Table 1: Bivariate analysis using PCOS status within case-control cohort.

|                      | PCOS (n = 74) | No PCOS (n = 222) | p value | N  |
|----------------------|--------------|-------------------|---------|----|
| Mean ± SD age (range)  | 35.9 ± 11.8  | (13–73)           | 36.0 ± 11.7 | (13–73) | 0.989 | 296 |
| Mean ± SD kg/m² BMI (range) | 31.2 ± 7.4  | (17.9–54.5)       | 31.0 ± 7.3 | (18.6–55.0) | 0.865 | 296 |
| Mean ± SD 24 hr urine panel (range): | Calcium (mg/day) | 211.2 ± 128.3 | (35.5–913.6) | 214.7 ± 119.7 | (16.7–817.1) | 0.848 | 251 |
|                      | Citrate (mg/day) | 624.1 ± 361.9 | (82–1903) | 527.5 ± 317.8 | (4–1546) | 0.083 | 220 |
|                      | Creatinine (g/day) | 1.3 ± 0.4   | (0.6–3.2) | 1.3 ± 0.41 | (0.1–2.9) | 0.316 | 230 |
|                      | Oxalate (mg/day) | 38.4 ± 15.2 | (17–113) | 39.1 ± 20.8 | (0–180) | 0.777 | 224 |
|                      | Sodium (mmol/day) | 135.7 ± 52.0 | (49–283) | 158.8 ± 76.3 | (28–442) | 0.015 | 211 |
|                      | Uric acid (mg/day) | 520.2 ± 194.6 | (179–1016) | 550.1 ± 210.2 | (30.3–1361.3) | 0.319 | 231 |
| Volume (ml/day) | 1643 ± 793.6 | (581–3440)       | 1690 ± 789.9 | (310–4450) | 0.712 | 188 |
| No. abnormality (%):  | Hypercalciuria (≥200 mg/day) | 35 | (53.9%) | 87 | (46.8%) | 0.402 | 251 |
|                      | Hypocitraturia (<550 mg/day) | 24 | (44.4%) | 95 | (57.2%) | 0.139 | 220 |
|                      | Hyperoxaluria (>40 mg/day) | 20 | (34.5%) | 58 | (34.9%) | 1.000 | 224 |
|                      | Hypernatriuria (>150 mmol/day) | 15 | (28.9%) | 81 | (50.9%) | 0.009 | 211 |
|                      | Hyperuricosuria (>750 mg/day) | 8 | (13.3%) | 29 | (17.0%) | 0.650 | 231 |
| Low volume (<2000 ml/day) | 35 | (66.0%) | 93 | (68.9%) | 0.839 | 188 |
| Mean ± SD stone composition % (range): | CaOMH | 45.4 ± 31.2 | (0–90) | 38.1 ± 31.4 | (0–90) | 0.286 | 239 |
|                      | CaODH | 16.9 ± 19.0 | (0–60) | 17.0 ± 20.4 | (0–90) | 0.985 | 239 |
|                      | CaPh | 25.2 ± 29.0 | (0–90) | 32.4 ± 34.6 | (0–100) | 0.270 | 239 |
|                      | CaHPh | 4.6 ± 17.2 | (0–80) | 2.0 ± 11.7 | (0–90) | 0.479 | 239 |
|                      | MAP | 2.3 ± 12.3 | (0–60) | 3.2 ± 12.9 | (0–70) | 0.791 | 239 |
|                      | UA | 1.7 ± 4.8 | (0–20) | 3.4 ± 15.9 | (0–100) | 0.240 | 239 |
| No. greater than 70% mixed (%)* | 11 | (45.8%) | 94 | (43.7%) | 1.000 | 239 |
| No. 70% or greater pure (%)* | 26.1 | 239 |

*Stones qualified as pure if the dominant component made up ≥ 70% of the stone.

Multivariate analysis of the PCOS patients using continuous free testosterone values did not reveal any statistically significant associations between 24-hour urine and stone composition parameters and free testosterone levels.

3.3. Stone Composition. Stone composition was recorded when present (24/74 PCOS patients, 215/222 controls). Stone composition assessment for the case-control cohort showed calcium oxalate monohydrate as the predominant component in both the PCOS patients and the controls (45.4% and 38.1%, respectively, Table 1). Mixed stone frequency was similar between the groups being present in 45.8% of the PCOS patients and 43.7% of the controls. Calcium oxalate monohydrate was the most frequent pure stone type in the PCOS group, while calcium phosphate was the most frequent amongst controls. Overall, stone composition assessment for both the testosterone and case-control cohorts did not reveal any statistically significant patterns in stone composition for either stone content quantitative or stone type qualitative parameters.

4. Discussion

4.1. PCOS-Nephrolithiasis Relationship. Even though the etiology of PCOS is still unclear, its clinical associations with hypertension, insulin resistance, and abdominal obesity due to androgen excess have been successfully documented [10–13]. However, the potential clinical association with kidney stones is still unexplored. We attempted to characterize the 24-hour urine metabolic and stone composition parameters of PCOS via our case-control cohort. Only sodium showed significant variations between PCOS patients with stones and our control group. Of relevance to this observation, there is evidence that sex differences can impact osmotic regulation of vasopressin and renal sodium handling, most likely due to alterations in testosterone and estrogen levels [14]. While we cannot make any definitive conclusions based on these findings, the broad hormonal changes in PCOS may be driving these differences in sodium excretion; however, menstrual cycle phase can also impact these outcomes that were not able to account for in our sample.

Polycystic ovary syndrome has also been linked to increased rates of the metabolic syndrome with an estimated prevalence of 33–43% in PCOS patients and a statistically
Table 2: Bivariate analysis using categorical testosterone levels within the PCOS cohort.

|                          | High testosterone (n = 38) | Normal testosterone (n = 36) | p value | N  |
|--------------------------|----------------------------|-----------------------------|---------|----|
| Mean ± SD age (range)    | 32.4 ± 8.2 (14.9–57.0)     | 39.7 ± 13.8 (13.6–73.69)    | 0.008   | 74 |
| Mean ± SD kg/m² BMI (range) | 34.3 ± 7.0 (21.0–54.5)     | 27.9 ± 6.3 (17.93–48.79)   | <0.001  | 74 |
| Mean ± SD 24 hr urine panel (range) | Calcium (mg/day) | 223.7 ± 158.5 (35.5–913.6) | 198.3 ± 87.7 (50.5–366.7) | 0.426 | 65 |
|                          | Citrate (mg/day)           | 709.6 ± 411.7 (118–1903)   | 517.1 ± 257.9 (82–956)    | 0.041 | 54 |
|                          | Creatinine (g/day)         | 1.3 ± 0.5 (0.6–3.2)        | 1.2 ± 0.3 (0.6–1.6)       | 0.224 | 56 |
|                          | Oxalate (mg/day)           | 37.6 ± 12.3 (17–66)        | 39.3 ± 18.3 (19–113)      | 0.681 | 58 |
|                          | Sodium (mmol/day)          | 144.4 ± 54.1 (49–282)      | 123.8 ± 47.8 (52–283)     | 0.154 | 52 |
|                          | Uric acid (mg/day)         | 565.3 ± 225.2 (179–1016)   | 461.4 ± 126.9 (208–739)   | 0.028 | 60 |
|                          | Volume (ml/day)            | 1721.8 ± 822.9 (581–3440)  | 1561.1 ± 769.6 (590–3259) | 0.466 | 53 |
| No. abnormality (%)      |                            |                             |                     |      |
| Hypercalciuria (>200 mg/day) | 17 (51.5%)                | 18 (56.3%)                 | 0.893   | 65 |
| Hypocitraturia (<550 mg/day) | 11 (36.7%)                | 13 (54.2%)                 | 0.312   | 54 |
| Hyperoxaluria (>40 mg/day) | 13 (41.9%)                | 7 (25.9%)                  | 0.316   | 58 |
| Hypernatriuria (>150 mmol/day) | 12 (40.0%)               | 3 (13.6%)                  | 0.078   | 52 |
| Hyperuricosuria (>750 mg/day) | 8 (23.5%)               | 0 (0%)                     | 0.008   | 60 |
| Low volume (<2000 ml/day) | 17 (63.0%)                | 18 (69.2%)                 | 0.848   | 53 |
| Mean ± SD stone composition % (range) | CaOMH | 35.7 ± 31.8 (0–80) | 59.0 ± 26.0 (0–90) | 0.062 | 24 |
|                          | CaODH                     | 16.4 ± 17.8 (0–60)         | 17.5 ± 21.5 (0–50)       | 0.899 | 24 |
|                          | CaPh                      | 31.4 ± 31.8 (0–90)         | 16.5 ± 23.3 (0–80)       | 0.199 | 24 |
|                          | CaHPh                     | 7.9 ± 22.3 (0–80)          | —                  | 0.209 | 24 |
|                          | MAP                       | 4.3 ± 16.0 (0–60)          | —                  | 0.336 | 24 |
|                          | UA                        | 0.7 ± 2.7 (0–10)           | 3.0 ± 6.8 (0–20)        | 0.332 | 24 |
| No. greater than 70% mixed (%)* | 7 (50%)                  | 4 (40%)                    | 1.000   | 24 |

No adjustments made for confounding variables, original analysis only, and therefore, p values not referenced in discussion. *Stones qualified as pure if the dominant component made up ≥70% of the stone.

Table 3: Multivariate analysis using categorical testosterone levels within the PCOS cohort.

|                          | β coefficient | Standard error | p value | N  |
|--------------------------|---------------|----------------|---------|----|
| Mean ± SD 24 hr urine panel (range): | Calcium (mg/day) | −32.4 | 38.8 | 0.406 | 65 |
|                          | Citrate (mg/day) | −246.3 | 117.4 | 0.041 | 54 |
|                          | Creatinine (g/day) | −0.1 | 0.1 | 0.691 | 56 |
|                          | Oxalate (mg/day) | 1.8 | 4.8 | 0.705 | 58 |
|                          | Sodium (mmol/day) | −36.7 | 18.9 | 0.058 | 52 |
|                          | Uric acid (mg/day) | −28.4 | 57.2 | 0.621 | 60 |
|                          | Volume (ml/day) | −449.5 | 238.7 | 0.066 | 53 |
| Mean ± SD stone composition % (range): | CaOMH | 11.9 | 13.6 | 0.392 | 24 |
|                          | CaODH | 3.6 | 10.9 | 0.743 | 24 |
|                          | CaPh | 2.5 | 12.9 | 0.851 | 24 |
|                          | CaHPh | −14.4 | 9.5 | 0.144 | 24 |
|                          | MAP | −9.6 | 6.3 | 0.145 | 24 |
|                          | UA | 1.8 | 2.4 | 0.481 | 24 |
| Logistic regression: | Odds ratio | 95% CI | p value | N  |
| No. abnormality (%): | Hypercalciuria (>200 mg/day) | 1.0 | 0.32–3.33 | 0.955 | 65 |
|                          | Hypocitraturia (<550 mg/day) | 0.2 | 0.04–0.94 | 0.042 | 54 |
|                          | Hyperoxaluria (>40 mg/day) | 1.9 | 0.50–7.14 | 0.340 | 58 |
|                          | Hypernatriuria (>150 mmol/day) | 13.3 | 1.49–100 | 0.021 | 52 |
|                          | Hyperuricosuria (>750 mg/day) | 6250 | 4 × 10^{-22}−9 × 10^{-16} | 0.693 | 60 |
| Low volume (<2000 ml/day) | 0.2 | 0.04–1.19 | 0.079 | 53 |
| No. greater than 70% mixed (%)* | 1.0 | 0.11–9.09 | 0.978 | 24 |

Note: confounding variables adjusted for age, BMI, and metformin status with high or normal testosterone classification as an independent variable. Odds ratio is reported as the likelihood of a high testosterone PCOS patient having a given urine or stone analysis finding. Negative β coefficient indicates an elevation of that parameter in the high testosterone cohort. CI = confidence interval.
High free testosterone classification was associated in our published reference ranges [9].

Both our data and these observations indicate that a potential relationship between PCOS and kidney stones may not be directly related to hyperandrogenism but rather the obesity, metabolic syndrome, and/or insulin resistance that are frequently associated with this syndrome. It seems that urinary metabolic and stone composition data on PCOS patients compared with stone forming controls for age and BMI are not sufficient to determine whether PCOS is an independent risk factor for stone formation. Further prospective data regarding the prevalence of kidney stones in PCOS patients and potential associations within that group for obesity and the metabolic syndrome may shed more light on the issue.

4.2. Testosterone-Nephrolithiasis Relationship. The association between PCOS and hyperandrogenism offers an opportunity to explore the relationship between testosterone and urolithiasis [2]. However, PCOS is also a complex endocrine disorder with a variety of clinical signs, including variations in hyperandrogenism, which makes it heterogeneous and difficult to diagnose [10]. Therefore, the lack of significant differences in our case-control cohort may have been due to our sample including a mixture of elevated and normal testosterone PCOS patients. Future studies may choose to look at only a subset of actively hyperandrogenic or newly diagonsed PCOS patients to account for this variation. This clinical variability in androgen levels could be due to both variations in treatment or disease severity. In light of these variations, we also chose to examine the impact of testosterone values within our PCOS group while accounting for antiandrogenic and other medications used in the treatment of PCOS.

Previous studies on the associations between androgens and nephrolithiasis have reached divergent conclusions, possibly due to variations in use of total and/or free testosterone assays. Several investigators have reported that both free and total testosterone are elevated in stone forming patients [4, 7]. However, others reported that only total testosterone is elevated in stone-forming patients [5, 8]. Clouding the discussion further, one study reported an increased risk of stones with lower testosterone levels [20]. A single study found no association with testosterone [21]. Our endocrinologists only evaluate free testosterone due to previous evidence that it is more sensitive than total testosterone for the diagnosis of hyperandrogenic disorders such as PCOS [22]. Our cutoff for high free testosterone classification was set at >6.4 pg/mL due to previously published reference ranges [9].

4.3. Testosterone: Citrate, Natriuria, and Urinary Volume. High free testosterone classification was associated in our multivariable analysis with increased urinary citrate, sodium, and volume (Table 1). Regarding the increase in citrate excretion, previous literature has found that PCOS patients have increased rates of cortisol production as well as insulin-resistance-related increase in serum aldosterone [23, 24]. These two processes may be contributing to a metabolic alkalosis leading in turn to the increased citrate excretion we observed; however, we were not able to obtain a large enough sample of serum bicarbonate values to fully examine this possibility. Higher citrate and urinary volumes have been found to be protective against the formation of kidney stones [25]. This may support a prior study that reported increased urinary stone risk in those with lower testosterone levels [20].

Previous examinations into testosterone’s role in hypertension have indicated that testosterone may be driving a rightward shift in the pressure-natriuresis curve as well as contributing to increased interglomerular pressure [26]. Based on these findings, the respective increases in urine volume and sodium excretion among high testosterone PCOS patients could be secondary to this androgen-induced increase in interglomerular pressure and rightward shift in the pressure-natriuresis relationship.

4.4. Testosterone: Oxalate. Population data have shown that men have higher urinary oxalate excretion, an important promoter of lithogenesis [27]. Lee and colleagues noted decreased calcium oxalate stone formation in castrated male rats [3]. More recently, Nath, et al. reported significantly higher 24-hour urinary oxalate excretion in male stone formers and a positive association between free testosterone levels and urinary oxalate [4]. Despite these findings, we did not observe any significant changes in oxalate excretion within 24-hour urine metabolic panels or an increased frequency of calcium oxalate stones based on either PCOS or testosterone status.

4.5. Limitations. One major limitation to our study is its retrospective nature; however, a case-control methodology increases the likelihood that a difference in outcomes would be the result of PCOS. We also were not able to adjust for dietary factors that could impact 24-hour urine results or menstrual cycle timing that could impact free testosterone levels. It is also possible that the impact of androgens on stone risk in women may differ from that in men. Additionally, very few of the PCOS patients selected from the registry had stone composition analysis performed, which limited our analysis. Also, as a registry-based study, there is the possibility of bias regarding the criteria applied by different providers in assigning the diagnosis of polycystic ovarian syndrome.

5. Conclusions

When compared to matched cohort of healthy stone formers, PCOS patients did not demonstrate significant differences in 24-hour urine and stone composition values. It is possible that the potential relationship between PCOS and kidney stones may not be directly related to
hyperandrogenism but rather the obesity, metabolic syndrome, and/or insulin resistance that are frequently associated with this syndrome. Elevated free testosterone in PCOS patients demonstrated a significant association with higher sodium and urine volume, possibly secondary to an increased intraglomerular pressure and a rightward shift in the pressure-natriuresis relationship. This patient cohort may provide deeper insight into the interplay between androgens and stone formation; however, further study is needed to fully characterize the possible relationship between PCOS and stone formation.

**Abbreviations**

- CaOMH: Calcium oxalate monohydrate
- CaODH: Calcium oxalate dihydrate
- CaPh: Calcium phosphate
- CaHPh: Calcium hydrogen phosphate
- CI: Confidence interval
- LC/MS: Liquid chromatography tandem mass spectrometry
- MAP: Magnesium ammonium phosphate
- PCOS: Polycystic ovarian syndrome
- UA: Uric acid

**Data Availability**

Due to the policies of our institutional review board, we are unable to share the data obtained via our kidney stone registry with researchers outside of our institution at this time.

**Disclosure**

A poster and published abstract based on this work was previously presented at the National Kidney Foundation Spring Clinical Meetings 2018. Abstract citation: Fedrigon D, Alazem K, Sivalingam S, Monga M, Calle J. Polycystic Ovary Syndrome, Testosterone, and Urinary Stone Risk: A Matched Case Comparative Study. Am J Kidney Dis. 2018; 71(4):537. doi: http://10.1053/j.ajkd.2018.02.093.

**Conflicts of Interest**

The authors have no conflicts of interest to declare.

**References**

[1] R. S. Legro and J. F. Strauss, “Molecular progress in infertility: polycystic ovary syndrome,” *Fertility and Sterility*, vol. 78, no. 3, pp. 569–576, 2002.

[2] I. Kaygusuz, O. F. Karatas, H. Kafali, E. Cimentepe, and D. Unal, “Is polycystic ovarian syndrome a risk factor for urolithiasis?,” *Urolithiasis*, vol. 41, no. 4, pp. 361–362, 2013.

[3] Y. H. Lee, W. C. Huang, J. K. Huang, and L. S. Chang, “Testosterone enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats,” *The Journal of Urology*, vol. 156, no. 2, pp. 502–505, 1996.

[4] S. J. Nath, D. Sarma, P. K. Bagchi, S. K. Baruah, R. T. Puthveneetil, and S. J. Baruah, “The role of serum testosterone as a lithogenic factor and its correlation with stone and urine composition amongst male stone formers,” *UroToday International Journal*, vol. 6, no. 3, p. 37, 2013.

[5] J. M. Watson, A. B. Shrewsberry, S. Taghechian et al., “Serum testosterone may be associated with calcium oxalate urolithogenesis,” *Journal of Endourology*, vol. 24, no. 7, pp. 1183–1187, 2010.

[6] G. C. Curhan, “Epidemiology of stone disease,” *Urologic Clinics of North America*, vol. 34, no. 3, pp. 287–293, 2007.

[7] M. R. Naghii, M. Babaei, and M. Hedayati, “Androgens involvement in the pathogenesis of renal stones formation,” *PLoS One*, vol. 9, no. 4, pp. 1–4, 2014.

[8] K. Gupta, G. Gill, and R. Mahajan, “Possible role of elevated serum testosterone in pathogenesis of renal stone formation,” *International Journal of Applied and Basic Medical Research*, vol. 6, no. 4, pp. 241–244, 2016.

[9] G. D. Braunstein, R. E. Reitz, A. Buch, D. Schnell, and M. P. Caulfield, “Testosterone reference ranges in normally cycling healthy premenopausal women,” *The Journal of Sexual Medicine*, vol. 8, no. 10, pp. 2924–2934, 2011.

[10] E. Diamanti-Kandarakis, “Insulin resistance in PCOS,” *Endocrine*, vol. 30, no. 1, pp. 13–18, 2006.

[11] M.-J. Chen, W.-S. Yang, J.-H. Yang, C.-L. Chen, H.-N. Ho, and Y.-S. Yang, “Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome,” *Hypertension*, vol. 49, no. 6, pp. 1442–1447, 2007.

[12] H. F. Escobar-Morreale and J. L. S. Millán, “Abdominal adiposity and the polycystic ovary syndrome.” *Trends in Endocrinology & Metabolism*, vol. 18, no. 7, pp. 266–272, 2007.

[13] M. Luque-Ramírez, D. Martí, E. Fernández-Durán, M. Alpañés, F. Álvarez-Blasco, and H. F. Escobar-Morreale, “Office blood pressure, ambulatory blood pressure monitoring, and echocardiographic abnormalities in women with polycystic ovary syndrome,” *Hypertension*, vol. 63, no. 3, pp. 624–629, 2014.

[14] N. S. Stachenfeld, A. E. Splenser, W. L. Calzone, M. P. Taylor, and D. L. Keefe, “Selected contribution: sex differences in osmotic regulation of AVP and renal sodium handling,” *Journal of Applied Physiology*, vol. 91, no. 4, pp. 1893–1901, 2001.

[15] P. Essah and J. Nestler, “Metabolic syndrome in women with polycystic ovary syndrome,” *Fertility and Sterility*, vol. 86, pp. S18–S19, 2006.

[16] D. A. Ehrmann, D. R. Liljenquist, K. Kasza, R. Azizi, R. S. Legro, and M. N. Ghazii, “Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 91, no. 1, pp. 48–53, 2006.

[17] I. Gorbachinsky, H. Akpinar, and D. G. Assimos, “Metabolic syndrome and urologic diseases,” *Reviews in Urology*, vol. 12, no. 4, pp. e157–e180, 2010.

[18] E. N. Taylor, M. J. Stamper, and G. C. Curhan, “Obesity, weight gain, and the risk of kidney stones,” *JAMA*, vol. 293, no. 4, pp. 455–462, 2005.

[19] M. J. Semins, A. D. Shore, M. A. Makary, T. Magnuson, R. Johns, and B. R. Matlaga, “The association of increasing body mass index and kidney stone disease,” *Journal of Urology*, vol. 183, no. 2, pp. 571–575, 2010.

[20] A. Otunctemur, E. Ozbek, S. S. Cakir et al., “Urolithiasis is associated with low serum testosterone levels in men,” *Archivio Italiano di Urologia e Andrologia*, vol. 87, no. 1, pp. 83–86, 2015.
differences in development of nephrolithiasis,” Journal of Endourology, vol. 29, no. 12, pp. 1341–1345, 2015.

[22] R. Azziz, E. Carmina, D. Dewailly et al., “The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report,” Fertility and Sterility, vol. 91, no. 2, pp. 456–488, 2009.

[23] T. Cascella, S. Palomba, L. Tauchmanová et al., “Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 2, pp. 4395–4400, 2006.

[24] T. Tsilchorozidou, J. W. Honour, and G. S. Conway, “Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5α-reduction but not the elevated adrenal steroid production rates,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 12, pp. 5907–5913, 2003.

[25] O. W. Moe, “Kidney stones: pathophysiology and medical management,” The Lancet, vol. 367, no. 9507, pp. 333–344, 2006.

[26] J. F. Reckelhoff and J. P. Granger, “Role of androgens in mediating hypertension and renal injury,” Clinical and Experimental Pharmacology and Physiology, vol. 26, no. 2, pp. 127–131, 1999.

[27] K. K. Stamatelou, M. E. Francis, C. A. Jones, L. M. Nyberg, and G. C. Curhan, “Time trends in reported prevalence of kidney stones in the United States: 1976–1994,” Kidney International, vol. 63, no. 5, pp. 1817–1823, 2003.